Does Information from the Parkinson KinetiGraph™ (PKG) Influence the Neurologist's Treatment Decisions?-An Observational Study in Routine Clinical Care of People with Parkinson's Disease.
PKG
Parkinson’s disease
device
objective measurement
treatment
Journal
Journal of personalized medicine
ISSN: 2075-4426
Titre abrégé: J Pers Med
Pays: Switzerland
ID NLM: 101602269
Informations de publication
Date de publication:
05 Jun 2021
05 Jun 2021
Historique:
received:
01
05
2021
revised:
27
05
2021
accepted:
03
06
2021
entrez:
2
7
2021
pubmed:
3
7
2021
medline:
3
7
2021
Statut:
epublish
Résumé
Management of Parkinson's disease traditionally relies solely on clinical assessment. The PKG objectively measures affected persons' movements in daily life. The present study evaluated how often PKG data changed treatment decisions in routine clinical care and to what extent the clinical assessment and the PKG interpretation differed. PKG recordings were performed before routine visits. The neurologist first made a clinical assessment without reviewing the PKG. Signs and symptoms were recorded, and a treatment plan was documented. Afterward, the PKG was evaluated. Then, the neurologist decided whether to change the initial treatment plan or not. PKG review resulted in a change in the initial treatment plan in 21 of 66 participants (31.8%). The clinical assessment and the PKG review differed frequently, mainly regarding individual overall presence of motor problems (67%), profile of bradykinesia/wearing off (79%), dyskinesia (35%) and sleep (55%). PKG improved the dialogue with the participant in 88% of cases. PKG and clinical variables were stable when they were repeated after 3-6 months. In conclusion, PKG information changes treatment decisions in nearly a third of people with Parkinson's disease in routine care. Standard clinical assessment and PKG evaluation are often non-identical. Objective measurements in people living with Parkinson's disease can add therapeutically relevant information.
Identifiants
pubmed: 34198780
pii: jpm11060519
doi: 10.3390/jpm11060519
pmc: PMC8227056
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : Global Kinetics Corporation
ID : Kst 914 project 102805
Références
Parkinsonism Relat Disord. 2014 Jun;20(6):578-83
pubmed: 24674770
Mov Disord. 2005 Jun;20(6):726-33
pubmed: 15719426
J Clin Mov Disord. 2020 Apr 30;7:5
pubmed: 32377368
Brain. 2000 Nov;123 ( Pt 11):2297-305
pubmed: 11050029
Parkinsonism Relat Disord. 2014 Sep;20(9):969-74
pubmed: 24953743
Ann Med. 2001 Jul;33(5):337-43
pubmed: 11491192
Psychiatry (Edgmont). 2007 Jul;4(7):28-37
pubmed: 20526405
NPJ Parkinsons Dis. 2018 May 10;4:14
pubmed: 29761156
Eur Neuropsychopharmacol. 2005 Aug;15(4):473-90
pubmed: 15963700
Mov Disord. 2001 May;16(3):448-58
pubmed: 11391738
Expert Rev Neurother. 2018 Aug;18(8):669-680
pubmed: 30032695
NPJ Parkinsons Dis. 2020 Nov 20;6(1):35
pubmed: 33298955
PLoS One. 2014 Feb 24;9(2):e89319
pubmed: 24586685
Front Neurol. 2019 Oct 01;10:1027
pubmed: 31632333
J Parkinsons Dis. 2019;9(1):207-219
pubmed: 30412506
NPJ Parkinsons Dis. 2018 Apr 3;4:10
pubmed: 29644334
Lancet Neurol. 2009 May;8(5):464-74
pubmed: 19375664
Eur J Neurol. 2018 Mar;25(3):503-511
pubmed: 29193455
Mov Disord. 2006 Jul;21(7):916-23
pubmed: 16547944